Plasma Molecular Profiling in ALK Inhibitor Resistant NSCLC

Inclusion Criteria

• •Patients with advanced ALK fusion oncogene positive lung adenocarcinoma that have progressed after 1-2 ALK inhibitors, with at least one prior line of 2nd generation ALKi (i.e. Ceritinib, Alectinib, Brigatinib or Ensartinib)
• •The availability of sufficient plasma
• •Age ≥ 21 years
• •WHO performance status ≤ 2
• •Life expectancy of ≥ 21 weeks
• •Patients should have adequate organ function for potential consideration into clinical trials (routine blood tests are valid within 14 days before enrollment):
• •1. Adequate bone marrow function as shown by: ANC ≥ 1.0x10\^9/L, Platelets ≥ 75x10\^9/L, Hb ≥ 7.5 g/dL
• •2. Alanine aminotransferase (ALT) and aspirate aminotransferase (AST) normal range (or ≤ 3.0xULN if liver metastases are present)
• •Willing to provide signed informed consent
• •Patients whom do not fulfill the above criteria may be discussed on a case-by-case basis within the study team, for potential enrolment